La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Allarity Therapeutics Gestione

Gestione criteri di controllo 2/4

We currently do not have sufficient information about the CEO.

Informazioni chiave

Thomas Jensen

Amministratore delegato

US$24.7k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	20.6yrs
Proprietà del CEO	n/a
Durata media del management	20.6yrs
Durata media del Consiglio di amministrazione	1.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Thomas Jensen (46 yo)

20.6yrs

Mandato

US$24,720

Compensazione

Mr. Thomas H. Jensen is Co-Founder of Allarity Therapeutics, Inc. and serves as its Director since July 7, 2022. He is Chief Executive Officer since December 08, 2023 at Allarity Therapeutics, Inc. and ser...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Jensen	Founder	20.6yrs	US$24.72k	Nessun dato
Steen Knudsen	Founder & Chief Scientific Officer	20.6yrs	US$266.22k	0.000010% $ 0.7
Joan Brown	Chief Financial Officer	2.2yrs	US$250.00k	Nessun dato
Peter Jensen	Co-Founder	no data	US$128.02k	Nessun dato

20.6yrs

Durata media

66yo

Età media

Gestione esperta: ALLR's management team is seasoned and experienced (20.6 years average tenure).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Jensen	Founder	2.1yrs	US$24.72k	Nessun dato
Daniel Von Hoff	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Gerald McLaughlin	Independent Chairman of the Board	1.8yrs	US$107.38k	0% $ 0
Joyce O'Shaughnessy	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Mansoor Mirza	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Joseph Vazzano	Independent Director	less than a year	US$29.17k	Nessun dato
Laura Benjamin	Independent Director	less than a year	US$27.71k	Nessun dato
Ursula Matulonis	Member of Scientific Advisory Board	no data	Nessun dato	Nessun dato
Roberto Pili	Member of Scientific Advisory Board	2.2yrs	Nessun dato	Nessun dato

1.8yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: ALLR's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

Allarity Therapeutics Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Board Changes

Recent updates

Allarity Therapeutics Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance

Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer

Allarity Therapeutics, Inc., Annual General Meeting, Jul 26, 2024

Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial

Allarity Therapeutics, Inc. has withdrawn its Follow-on Equity Offering in the amount of $10 million.

Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib

Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement

Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)

Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer

Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)

Allarity Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $0.947 million.

Allarity Therapeutics, Inc. announced that it has received $0.6 million in funding

Allarity Therapeutics, Inc. announced that it has received $0.8 million in funding from 3i, LP

Allarity Therapeutics, Inc. Announces Resignation of James G. Cullem as Member of the Board

Allarity Therapeutics Announces Executive Changes

Allarity Therapeutics, Inc. Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP Companion Diagnostic

Allarity Therapeutics, Inc. Receives A Letter from Nasdaq Listing Qualifications Staff

Allarity Therapeutics Receives Notification from the Nasdaq Listing Qualifications Staff Regarding Non-Compliance with Listing Rule 5550(a)(2)

Allarity Therapeutics Announces Positive Early Data from an Ongoing Clinical Trial, and External Partnering for Its DRP Technology

Allarity Therapeutics, Inc. Announces the Publication of its Clinical Validation of a Novel Drug-Specific DRP-Companion Diagnostic (CDx) for Dovitinib in the Peer-Reviewed Journal PLOS ONE

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics, Inc. and Detsamma Investments Pty. Ltd. Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics

Allarity Therapeutics, Inc. Provides Nasdaq Compliance Update

Allarity Therapeutics, Inc. Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives

Allarity Therapeutics, Inc. Announces Initial Results from Its European Phase 2 Clinical Trial Evaluating the Efficacy of Ixempra®? in Metastatic Breast Cancer Patients

Allarity Therapeutics, Inc. announced that it expects to receive $0.35 million in funding from 3i, LP

Allarity Therapeutics Announces Reverse Stock Split of Common Stock to Bring it into Compliance with Nasdaq’s Listing Requirement Regarding Minimum Share Price

Allarity Therapeutics, Inc. Announces Results of Prospective Phase 2 Clinical Study

Allarity Therapeutics Announces Update on Delisting from The Nasdaq Stock Market

Allarity Therapeutics, Inc. Announces Board Changes

Allarity Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Market Value of Publicly Held Shares

High number of new and inexperienced directors

Allarity Therapeutics Receives Notice from the Nasdaq

Allarity Therapeutics Regains Compliance with NASDAQ Listing Requirements

Allarity Therapeutics GAAP EPS of -$0.72 misses by $0.46

Allarity Therapeutics, Inc. Announces the Appointment of Jerry Mclaughlin as a Member of its Board of Directors, Effective October 1, 2022

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics GAAP EPS of -$0.52 misses by $0.07

Allarity Therapeutics, Inc., Annual General Meeting, Nov 04, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Announces Appointment of New Members to Its Board of Directors

Allarity Therapeutics, Inc. Announces Executive Leadership Transition

Allarity Therapeutics appoints interim CEO, CFO

Allarity Therapeutics, Inc. Appoints Roberto Pili as Member of the Company’s Scientific Advisory Board

Allarity Therapeutics, Inc. Announces Impairment for the First Quarter Ended March 31, 2022

Allarity Therapeutics, Inc. announced delayed 10-Q filing

Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)

Allarity Therapeutics, Inc. announced delayed annual 10-K filing

Allarity Therapeutics, Inc. Receives Refusal to File Letters from U.S. FDA

Allarity Therapeutics Submits New Drug Application (NDA) to the U.S. FDA for Dovitinib for Third-Line Treatment of Renal Cell Carcinoma (RCC)

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media